Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Clinical Study to Evaluate the Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib Tablets in Patients With Myelofibrosis

Next Previous
Trial Profile

A Phase Ib/II Clinical Study to Evaluate the Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib Tablets in Patients With Myelofibrosis

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary) ; WJ 01024 (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Suzhou Junjing BioSciences

Most Recent Events

  • 30 Mar 2026 Status changed from recruiting to active, no longer recruiting.
  • 01 Oct 2025 Primary end-points are updated to remove DLT, MTD and RP2D.
  • 01 Oct 2025 Planned number of patients changed from 26 to 49.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top